Hepatic gene expression profiling of streptozotocin-induced diabetes

The method of claim 13, wherein said hepatic functional abnormalities are selected from the group consisting of:

• loss of hepatic insulin sensitivity;
• excessive protein breakdown;
• reduction of protein synthesis;
• excessive hepatic glucose production (gluconeogenesis);
• reduction in cell growth and regeneration;
• excessive cell death (apoptosis);
• serum dyslipidemia resulting from altered hepatic lipid and protein metabolism;
• altered drug, metabolite, and xenobiotic metabolism;
• enhanced oxidative damage and cellular stress;
• and enhanced inflammatory and disregulated immune responsiveness.

An assay for identifying a compound that modulates a polypeptide encoded by a polynucleotide selected from the group consisting of:

• polynucleotides listed in Table 1, said assay comprising the steps of:
• (a) contacting a compound with said polypeptide;
• and
• (b) determining the functional effect of the compound upon said polypeptide.

A high-throughput drug screening assay, wherein said method comprises the steps of:

• (a) contacting a cell isolated from a mammal with streptozotocin-induced diabetes with a test compound;
• (b) measuring the expression level of a polynucleotide selected from the group consisting of polynucleotides listed in Table 1;
• (c) comparing the expression level of said polynucleotide in a cell contacted with a test compound to the expression level of said polynucleotide in a cell from a control mammal,
• wherein said test compound that modulates the expression level of said polynucleotide is a candidate for the treatment of diabetes or diabetic complications.

A high-throughput assay for determining whether a test compound induces diabetes, wherein said method comprises the steps of:

• (a) contacting a cell isolated from a mammal with a test compound;
• (b) measuring the expression level of a polynucleotide selected from the group consisting of:
• polynucleotides listed in Table 1;
• and
• (c) determining whether said test compound modulates the expression level of said polynucleotide in the same manner as diabetes, wherein said test compound that modulates the expression level of said polynucleotide in the same manner as diabetes is a compound that induces diabetes.

A drug screening assay, wherein said method comprises the steps of:

• (a) administering a test compound to a mammal with streptozotocin-induced diabetes;
• (b) measuring the expression level of a polynucleotide selected from the group consisting of:
• polynucleotides listed in Table 1;
• and
• (c) comparing the expression level of said polynucleotide in a mammal contacted with a test compound to the expression level of said polynucleotide in a control mammal;
• wherein said test compound that modulates the expression level of said polynucleotide is a candidate for the treatment of diabetes or diabetic complications.

A assay for determining whether a test compound induces diabetes, wherein said method comprises the steps of:

• (a) administering a test compound to a mammal;
• (b) measuring the expression level of a polynucleotide selected from the group consisting of:
• polynucleotides listed in Table 1;
• and
• (c) determining whether said test compound modulates the expression level of said polynucleotide in the same manner as diabetes,
• wherein said test compound that modulates the expression level of said polynucleotide in the same manner as diabetes is a compound that induces diabetes.